Physician profile
Jasdeep S Badwal
NPI 1750723268
$10,957.31
in general payments reported to CMS, 2019-2025
32 companies · $2,296 in 2025
The $2,296 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,605 · 2020: $982 · 2021: $1,664 · 2022: $1,150 · 2023: $1,375 · 2024: $1,885 · 2025: $2,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,279 · Education: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,279.32 |
| Education | $276.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,587.24 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $1,827.91 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,227.97 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $699.62 | 2019-2025 | |
| Amgen INC. | $492.18 | 2022-2025 | Tezspire, Actimmune |
| Pfizer INC. | $440.43 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $430.60 | 2019-2025 | |
| Genentech USA, INC. | $423.76 | 2019-2025 | Xolair |
| Csl Behring | $367.54 | 2019-2025 | Andembry, Hizentra, Haegarda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $328.07 | 2019-2022 | |
| Abbvie INC. | $326.14 | 2021-2025 | Rinvoq |
| Optinose US, INC. | $265.94 | 2019-2025 | |
| Pharming Healthcare, INC. | $252.87 | 2019-2025 | Ruconest |
| Takeda Pharmaceuticals U.S.A., INC. | $249.26 | 2020-2025 | Cuvitru, Takhzyro |
| Grifols USA, LLC | $195.69 | 2022-2025 | Prolastin-C Liquid, Gamunex-C |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $138.61 | 2019 | |
| Blueprint Medicines Corporation | $104.41 | 2024-2025 | Ayvakit |
| Kaleo, INC. | $95.81 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $86.28 | 2019-2021 | |
| Ars Pharmaceuticals Operations, INC. | $76.24 | 2025 | Neffy |
| Lilly USA, LLC | $67.22 | 2025 | Ebglyss |
| Gc Biopharma USA, INC. | $50.87 | 2024-2025 | Alyglo, Alyglo |
| Sanofi-Aventis U.S. LLC | $35.85 | 2019-2021 | |
| Leo Pharma INC. | $34.30 | 2022 | |
| Incyte Corporation | $25.70 | 2025 | Opzelura |
| Octapharma USA, INC. | $23.22 | 2019 | |
| Phadia US INC. | $22.40 | 2024 | Immunocap |
| Horizon Therapeutics Plc | $20.10 | 2022 | |
| Merck Sharp & Dohme LLC | $17.04 | 2023 | |
| Uswm, LLC | $17.00 | 2021 | |
| Circassia INC. | $13.64 | 2019 | |
| Alk-Abello, INC | $13.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasdeep Badwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.